SCHEDULE: Baker Bros. Advisors Discloses 5% Stake in Revolution Medicines

Baker Bros. Advisors LP and its affiliates have reported a 5.0% beneficial ownership stake in Revolution Medicines, Inc., totaling 9,364,972 shares of common stock.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing discloses their beneficial ownership of 9,364,972 shares of Common Stock in Revolution Medicines, Inc.
• This ownership represents 5.0% of the outstanding Common Stock of Revolution Medicines, Inc.
• The percentage is based on 186,901,268 shares of Common Stock outstanding as of June 30, 2025, as reported in Revolution Medicines' Form 10-Q filed on August 6, 2025.
• The shares are held through Baker Brothers Life Sciences, L.P. (4.6%) and 667, L.P. (0.4%).
• The Reporting Persons hold sole voting and sole dispositive power over these shares.
• Prefunded Warrants are mentioned but are not currently exercisable due to a 4.99% beneficial ownership limitation, which can be increased to 19.99% with 61 days' notice.

Sentiment

Score: 8

Explanation: The disclosure of a 5.0% stake by Baker Bros. Advisors, a highly respected and specialized biotech investor, is generally perceived as a strong positive signal, indicating confidence in the company's value and future prospects.

Positives

• Baker Bros. Advisors, a prominent investment firm specializing in the life sciences sector, holding a significant 5.0% stake, signals confidence in Revolution Medicines, Inc.'s long-term prospects and strategic direction.
• The substantial investment by a sophisticated biotech investor may attract further institutional interest and validate the company's potential.

Risks

• The existence of Prefunded Warrants, while currently unexercisable due to ownership limitations, presents a potential future dilution risk if the holders choose to increase their maximum percentage and exercise these warrants.

Future Outlook

The filing indicates that Prefunded Warrants held by the Funds are not currently exercisable due to a 4.99% beneficial ownership limit, but this limit can be increased to 19.99% with 61 days' written notice to the Issuer, potentially allowing for future exercise and changes in ownership structure.

Industry Context

Baker Bros. Advisors is a highly specialized and influential investment firm within the biotechnology and life sciences sectors. Their significant stake in Revolution Medicines, Inc. aligns with their strategy of investing in companies with strong therapeutic pipelines and growth potential, suggesting a positive long-term view of Revolution Medicines' position within the competitive pharmaceutical industry.

Comparison to Industry Standards

• A 5.0% stake by a dedicated biotech fund like Baker Bros. Advisors is a substantial position, often indicative of a high-conviction investment, similar to other strategic investments seen in the biotech sector where specialized funds take significant early or growth-stage positions.
• While specific comparable companies or projects are not detailed in this filing, Baker Bros. has a history of significant investments in companies such as Incyte Corporation, Seattle Genetics, and Array BioPharma, where their involvement often preceded or coincided with periods of significant growth or strategic developments.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a prominent institutional investor may positively influence investor sentiment and potentially the stock price, signaling confidence in the company.
• Management: The presence of a large, active investor like Baker Bros. may lead to increased scrutiny or engagement regarding strategic decisions and corporate performance.

Key Dates

Recommendation

The disclosure of a 5.0% beneficial ownership by Baker Bros. Advisors, a highly regarded and specialized investor in the life sciences sector, suggests a strong conviction in Revolution Medicines' long-term potential. Such a significant stake from a sophisticated investor often signals a positive outlook on the company's pipeline, strategy, and valuation, making it an attractive consideration for investment.

Keywords

Revolution Medicines, Baker Bros. Advisors, Biotechnology, Pharmaceuticals, Investment, Common Stock, Beneficial Ownership, SEC Filing, Schedule 13G